⌘K
t
| Date | 3 Jul 2025 |
| Time | 13:04:09 |
| Category | Miscellaneous |
| ID | 6535P |
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
03 July 2025
AQSE: EDX
("EDX Medical" or the "Group" or "Company")
RESULT OF GENERAL MEETING
The General Meeting of EDX Medical Group plc was held at Heritage Centre, 1 Wimpole Street, Westminster, London, W1G 0AE on 3 July 2025 at 11:00am.
Both resolutions put to members were passed on a poll. Resolution 1 was passed as an ordinary resolution and resolution 2 was passed as a special resolution.
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
|
Resolution |
Votes for |
% |
Votes against |
% |
Votes withheld |
|
Resolution 1 (Ordinary) To authorise the Directors to allot securities in line with the limits set out in the General Meeting Notice. |
181,853,678 |
94.55 |
10,491,190 |
5.45 |
33,089 |
|
Resolution 2 (Special) To authorise the Directors, subject to resolution 1, to allot Equity Securities for cash as if section 561 of the Companies Act 2006 did not apply, as set out in the General Meeting Notice. |
181,853,678 |
94.55 |
10,491,190 |
5.45 |
33,089 |
As at 3 July 2025, there were 372,308,871 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
The full text of each resolution is available in the Notice of General Meeting, published on our website.
ENDS
Contacts
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer) |
+44 (0)7812 345 301 |
|
|
|
|
Oberon Capital |
|
|
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking) |
+44 (0)20 3179 5300 |
|
|
|
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856 ramsay@mediahouse.co.uk + 44 (0)7834 694609 gary@mediahouse.co.uk |
|
|
|
|
IFC Advisory (Investor Relations) |
|
|
Tim Metcalfe Graham Herring |
+44 (0)20 3934 6630 |
Notes for Editors:
About EDX Medical Group plc
The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.